Most Read Articles
Dr Margaret Shi, 18 May 2020

A blood test is shown to be feasible and safe for early detection of multiple cancers in women with no current or known history of cancer, enabling early treatment with curative intent in a subset of individuals.

Christina Lau, 12 May 2020

Patients with advanced non-small-cell lung cancer (NSCLC) who have a past medical history of pneumonitis are at increased risk of treatment-related pneumonitis (TAP) from immune checkpoint inhibitor (ICI) regimens or chemotherapy alone, an analysis of clinical trial and real-world data has shown.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.
Dr Margaret Shi, 14 May 2020
Pembrolizumab monotherapy improves overall survival (OS) and cancer control compared with platinum-based chemotherapy in patients with untreated locally advanced or metastatic programmed death-ligand 1 (PD-L1)–positive non-small-cell lung cancer (NSCLC) regardless of STK11 or KEAP1 mutation status, according to results of the phase III KEYNOTE-042 study. 

Macular sparing, optic nerve visibility predict low-risk histopathology in unilateral retinoblastoma

20 Sep 2019

Low-risk histopathologic features at primary enucleation are predicted by the presence of macular sparing, optic nerve visibility, <1 quadrant of retinal detachment (RD) or a combination thereof, which suggest safe trial eye salvage, according to a study. No clinical sign is associated with high-risk histopathologic features.

Thirty-eight eyes with vitreous seeding and normal intraocular pressure were included. The median diagnosis to enucleation interval was 4 days (range, 0–14 days). Histopathologic analysis diagnosed four (10.5 percent) high-risk and 34 (89.5 percent) low-risk eyes.

High-risk eyes were shown to have massive choroidal invasion (n=4) or trans-scleral, extraocular and postlaminar optic nerve invasion (n=1). Clinical findings were as follows: macular involvement (n=31), complete optic nerve obscuration (n=27) and RD (n=28).

Of the eyes with high-risk histopathologic features, 13 percent (4/31; 95 percent CI, 1–25 percent) had macular involvement, 15 percent (4/27; 1–28 percent) had complete optic nerve obscuration, and 14 percent (4/28; 1–27 percent) had RD.

Macular sparing (7/7; 47–100 percent), optic nerve visibility (10/10; 63–100 percent) and <1 quadrant of RD (10/10; 63–100 percent) predicted low-risk histopathologic features.

Furthermore, one child who lacked all three clinical low-risk predictive features with high-risk histopathologic features (pT3a) developed metastases and died. The other children were alive and well (mean follow-up, 65 months).

This retrospective, noncomparative, single-institutional, observational case series included children with unilateral cT2b/group D retinoblastoma managed with primary enucleation at the Hospital for Sick Children in Toronto, Canada, from January 2008 through February 2018.

The authors obtained and assessed the following data: clinical features (ie, intraocular pressure, optic nerve obscuration, macular involvement, tumour seeding and serous RD >1 quadrant), timing to enucleation, histopathologic features and follow-up.

“Attempted eye salvage for unilateral retinoblastoma may risk tumour spread compared with primary enucleation,” the investigators noted.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr Margaret Shi, 18 May 2020

A blood test is shown to be feasible and safe for early detection of multiple cancers in women with no current or known history of cancer, enabling early treatment with curative intent in a subset of individuals.

Christina Lau, 12 May 2020

Patients with advanced non-small-cell lung cancer (NSCLC) who have a past medical history of pneumonitis are at increased risk of treatment-related pneumonitis (TAP) from immune checkpoint inhibitor (ICI) regimens or chemotherapy alone, an analysis of clinical trial and real-world data has shown.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.
Dr Margaret Shi, 14 May 2020
Pembrolizumab monotherapy improves overall survival (OS) and cancer control compared with platinum-based chemotherapy in patients with untreated locally advanced or metastatic programmed death-ligand 1 (PD-L1)–positive non-small-cell lung cancer (NSCLC) regardless of STK11 or KEAP1 mutation status, according to results of the phase III KEYNOTE-042 study.